Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Xia

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Eclinicalmedicine|August 18, 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialYuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
Nature Medicine|May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trialXiangyu Gao, Ke Ji, Yongning Jia, et al.
Oral Oncology|February 22, 2024
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter studyQiu-Yan Chen, Shan-Shan Guo, Ying Luo, et al.
Journal of Hepatology|July 6, 2026
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trialQi Xu, Shurui Zhou, Chenbo Zhang, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
The Lancet. Oncology|October 5, 2023
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialXiangyu Gao, Nong Xu, Ziyu Li, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Eclinicalmedicine|August 18, 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trialYuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
Nature Medicine|May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trialXiangyu Gao, Ke Ji, Yongning Jia, et al.
Oral Oncology|February 22, 2024
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter studyQiu-Yan Chen, Shan-Shan Guo, Ying Luo, et al.
Journal of Hepatology|July 6, 2026
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trialQi Xu, Shurui Zhou, Chenbo Zhang, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
The Lancet. Oncology|October 5, 2023
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialXiangyu Gao, Nong Xu, Ziyu Li, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Pageof 4